Mangalam Drugs & Organics Posts ₹4,440 Lakh Consolidated Net Loss in FY26
Mangalam Drugs and Organics Limited reported a consolidated net loss of ₹4,440.00 lakh for the year ended March 31, 2026, reversing from a net profit of ₹672.07 lakh in the prior year, as consolidated revenue from operations declined sharply to ₹23,213.27 lakh from ₹31,757.60 lakh. The Board approved the results on May 14, 2026, and the audited financial results were subsequently published in Financial Express and Loksatta newspapers, with copies submitted to stock exchanges on May 15, 2026. On a standalone basis, the net loss stood at ₹4,381.42 lakh, while total consolidated assets declined to ₹31,496.93 lakh from ₹36,642.17 lakh.
*this image is generated using AI for illustrative purposes only.
Mangalam Drugs and Organics Limited reported a sharp reversal in financial performance for the quarter and fiscal year ended March 31, 2026, swinging to a consolidated net loss of ₹4,440.00 lakh from a net profit of ₹672.07 lakh in the previous year. The Board of Directors approved both the standalone and consolidated audited financial results at their meeting held on May 14, 2026. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited financial results were subsequently published in Financial Express and Loksatta newspapers, with the advertisement copies submitted to the stock exchanges on May 15, 2026 by Chairman and Managing Director Govardhan M. Dhoot. The results were prepared in accordance with Indian Accounting Standards (Ind AS) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors V.S. Somani & Co., Chartered Accountants, issued an unmodified audit opinion on both the standalone and consolidated financial results.
Consolidated Annual Financial Performance
On a consolidated basis, revenue from operations for the year declined significantly to ₹23,213.27 lakh from ₹31,757.60 lakh in the prior year. Total income stood at ₹23,289.58 lakh against ₹31,873.28 lakh previously. Total expenses for the year were ₹28,146.72 lakh compared to ₹31,394.70 lakh in the prior year. The consolidated loss before tax for the year was ₹4,857.14 lakh against a profit before tax of ₹478.58 lakh in the previous year. After a net tax credit of ₹417.13 lakh, the net loss stood at ₹4,440.00 lakh. Total comprehensive loss for the year was ₹4,485.24 lakh. The basic and diluted earnings per share (EPS) for the year were reported at a loss of ₹28.05, compared to an EPS of ₹4.25 in the previous year.
The following table summarises the key consolidated annual financial results:
| Particulars: | Year Ended 31.03.2026 (₹ in Lakhs) | Year Ended 31.03.2025 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations: | 23,213.27 | 31,757.60 |
| Total Income: | 23,289.58 | 31,873.28 |
| Total Expenses: | 28,146.72 | 31,394.70 |
| Loss/Profit Before Tax: | (4,857.14) | 478.58 |
| Net Profit/(Loss): | (4,440.00) | 672.07 |
| Total Comprehensive Income/(Loss): | (4,485.24) | 1,318.62 |
| Basic & Diluted EPS (₹): | (28.05) | 4.25 |
Quarterly Consolidated Results
For the quarter ended March 31, 2026, the company reported a consolidated net loss of ₹1,342.00 lakh, compared to a net profit of ₹5.94 lakh in the corresponding quarter of the previous year. Revenue from operations for the quarter was ₹6,728.71 lakh, while total income stood at ₹6,737.65 lakh. Total expenses for the quarter amounted to ₹8,064.79 lakh. The basic and diluted EPS for the quarter was a loss of ₹8.48.
| Particulars: | Q4 FY26 (₹ in Lakhs) | Q3 FY26 (₹ in Lakhs) | Q4 FY25 (₹ in Lakhs) |
|---|---|---|---|
| Revenue from Operations: | 6,728.71 | 5,837.64 | 7,277.73 |
| Total Income: | 6,737.65 | 5,859.83 | 7,324.90 |
| Total Expenses: | 8,064.79 | 6,843.33 | 7,161.45 |
| Net Profit/(Loss): | (1,342.00) | (983.55) | 5.94 |
| Basic & Diluted EPS (₹): | (8.48) | (6.21) | 0.04 |
Standalone Financial Performance
On a standalone basis, the company reported a net loss of ₹4,381.42 lakh for the year ended March 31, 2026, compared to a net profit of ₹692.43 lakh in the previous year. Standalone revenue from operations was ₹23,213.27 lakh against ₹31,757.60 lakh previously. Total standalone expenses for the year were ₹28,088.32 lakh. The standalone basic and diluted EPS for the year was a loss of ₹27.68, compared to a profit of ₹4.37 in the prior year. Total comprehensive loss on a standalone basis was ₹4,426.66 lakh. For the quarter ended March 31, 2026, the standalone net loss was ₹1,306.04 lakh, with basic and diluted EPS of ₹(8.25), compared to a net profit of ₹15.09 lakh in the corresponding quarter of the previous year.
| Particulars: | Year Ended 31.03.2026 (₹ in Lakhs) | Year Ended 31.03.2025 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations: | 23,213.27 | 31,757.60 |
| Total Income: | 23,289.58 | 31,872.77 |
| Total Expenses: | 28,088.32 | 31,373.83 |
| Net Profit/(Loss): | (4,381.42) | 692.43 |
| Total Comprehensive Income/(Loss): | (4,426.66) | 630.86 |
| Basic & Diluted EPS (₹): | (27.68) | 4.37 |
Standalone Quarterly Results
| Particulars: | Q4 FY26 (₹ in Lakhs) | Q3 FY26 (₹ in Lakhs) | Q4 FY25 (₹ in Lakhs) |
|---|---|---|---|
| Revenue from Operations: | 6,728.71 | 5,837.64 | 7,277.73 |
| Total Income: | 6,737.65 | 5,859.83 | 7,324.91 |
| Total Expenses: | 8,029.02 | 6,837.72 | 7,152.31 |
| Net Profit/(Loss): | (1,306.04) | (977.94) | 15.09 |
| Basic & Diluted EPS (₹): | (8.25) | (6.18) | 0.10 |
Consolidated Balance Sheet Highlights
The consolidated balance sheet as at March 31, 2026 reflects total assets of ₹31,496.93 lakh, down from ₹36,642.17 lakh as at March 31, 2025. Total equity stood at ₹10,305.90 lakh compared to ₹14,897.90 lakh in the prior year, reflecting the impact of the net loss for the year. Current borrowings rose to ₹9,455.80 lakh from ₹7,095.51 lakh, while inventories declined to ₹10,277.36 lakh from ₹13,880.18 lakh. Consolidated cash and cash equivalents at the close of the year stood at ₹70.10 lakh, down from ₹258.89 lakh at the start of the year.
| Balance Sheet Item: | As at 31.03.2026 (₹ in Lakhs) | As at 31.03.2025 (₹ in Lakhs) |
|---|---|---|
| Total Assets: | 31,496.93 | 36,642.17 |
| Total Equity: | 10,305.90 | 14,897.90 |
| Total Non-current Liabilities: | 1,532.99 | 2,584.33 |
| Total Current Liabilities: | 19,658.04 | 19,159.93 |
| Cash and Cash Equivalents: | 70.10 | 258.89 |
Operational and Corporate Updates
The group's business activity falls within a single reportable segment: "Manufacturing of Bulk Drugs." The consolidated results include the financials of Mangalam Laboratories Private Limited (MLPL), a wholly-owned subsidiary, which is not classified as a material subsidiary. The subsidiary reported total assets (before consolidation adjustments) of ₹687.51 lakh, total revenue (before consolidation adjustments) of ₹30.45 lakh, and a total net loss after tax (before consolidation adjustments) of ₹58.58 lakh for the year. The Board had previously approved a scheme of merger by absorption of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited with the company, subject to approval of the National Company Law Tribunal, with the hearing scheduled for June 2, 2026. The company also noted that the Government of India notified four Labour Codes consolidating 29 existing labour laws, and based on management assessment, the incremental impact of these changes is not material to the financial results for the year.
Historical Stock Returns for Mangalam Drugs & Organics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.61% | -3.73% | +2.40% | -36.60% | -62.58% | -78.42% |
What specific restructuring measures or cost-reduction strategies is Mangalam Drugs and Organics planning to implement to return to profitability given the ₹4,440 lakh net loss and rising current borrowings?
How might the outcome of the NCLT hearing on June 2, 2026 for the merger of Mangalam Laboratories and Shri JB Pharma impact the company's consolidated balance sheet and operational efficiency going forward?
Given the sharp 27% decline in revenue from operations, what are the key demand or pricing pressures in the bulk drugs segment that could continue to weigh on the company's top line in FY27?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
